Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line

被引:10
|
作者
Rhee, MS
Schneider, E
机构
[1] New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA
[2] SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY 12201 USA
关键词
drug resistance; methotrexate; breast cancer resistance protein; polyglutamylation; folate metabolism;
D O I
10.1016/j.bcp.2004.09.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Accumulation of methotrexate (MTX) and its polyglutamates (PGs) has been recognized as an important factor in MTX efficacy. We have previously described a multidrug-resistant human breast cancer cell line, MCF7/MX, that exhibits reduced accumulation of total MTX as well as MTX-PGs, and that is resistant to continuous MTX exposure [Volk EL, Rohde K, Rhee M, McGuire JJ, Doyle LA, Ross DD, et al. Methotrexate cross-resistance in a mitoxantrone selected multidrug-resistant MCF7 breast cancer cell line is due to enhanced energy-dependent drug efflux. Cancer Res 2000;60:3514-21]. These cells express high levels of the breast cancer resistance protein (BCRP/ABCG2) that has been shown to actively transport MTX and short-chain MTX-PGs in vitro. However, the effect of BCRP on MTX-PG accumulation in intact cells was unclear. Here, we show that MTX transport by BCRP is required for the observed lower levels of MTX-PGs in the resistant cells. When BCRP was inhibited with fumitremorgin C, or in cells expressing a mutated form of BCRP that is unable to transport MTX, MTX-PG accumulation was similar or even higher than that in the parental cells that do not express BCRP. Concomitantly, there was increased inhibition of thymidylate synthase. It had previously been suggested that BCRP-mediated efflux of MTX-PGs contributed to the reduced MTX-PG accumulation. However, we found no evidence of BCRP-mediated efflux of MTX-PGs from intact cells, suggesting that direct efflux of MTX-PGs does not play a major role in MTX resistance. Together, these data show that BCRP overexpression can cause a reduction in total MTX accumulation as well as a reduction in the proportion of long-chain MTX-PGs. In contrast, BCRP overexpression did not affect natural folate accumulation or the relative distribution of folylpolyglutamates in the resistant, as compared to the parental, cells. Thus, it appears that BCRP overexpression affects the metabolism of the antifolate MTX, but not that of natural folates, although indirect effects cannot be excluded. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:123 / 132
页数:10
相关论文
共 50 条
  • [41] The sulfated conjugate of biochanin A is a substrate of breast cancer resistant protein (ABCG2)
    An, Guohua
    Morris, Marilyn E.
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2011, 32 (08) : 446 - 457
  • [42] Structure–Activity Relationships and Quantitative Structure–Activity Relationships for Breast Cancer Resistance Protein (ABCG2)
    Yash A. Gandhi
    Marilyn E. Morris
    The AAPS Journal, 2009, 11 : 541 - 552
  • [43] Clinical Significance of ABCG2/BCRP Quantified by Fluorescent Nanoparticles in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
    Tada, Hiroshi
    Gonda, Kohsuke
    Kitamura, Narufumi
    Ishida, Takanori
    CANCERS, 2023, 15 (08)
  • [44] Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP)
    Gupta, Anshul
    Unadkat, Jashvant D.
    Mao, Qingcheng
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2007, 96 (12) : 3226 - 3235
  • [45] Characterization of a Potent, Selective, and Safe Inhibitor, Ac15(Az8)2, in Reversing Multidrug Resistance Mediated by Breast Cancer Resistance Protein (BCRP/ABCG2)
    Chong, Tsz Cheung
    Wong, Iris L. K.
    Cui, Jiahua
    Law, Man Chun
    Zhu, Xuezhen
    Hu, Xuesen
    Kan, Jason W. Y.
    Yan, Clare S. W.
    Chan, Tak Hang
    Chow, Larry M. C.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (21)
  • [46] Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells
    Nakatomi, K
    Yoshikawa, M
    Oka, M
    Ikegami, Y
    Hayasaka, S
    Sano, K
    Shiozawa, K
    Kawabata, S
    Soda, H
    Ishikawa, T
    Tanabe, S
    Kohno, S
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 288 (04) : 827 - 832
  • [47] Drug Transport Across the Blood-Brain Barrier and the Impact of Breast Cancer Resistance Protein (ABCG2)
    Nicolazzo, Joseph A.
    Katneni, Kasiram
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2009, 9 (02) : 130 - 147
  • [48] CHARACTERIZATION OF CROSS-RESISTANCE TO METHOTREXATE IN A HUMAN BREAST-CANCER CELL-LINE SELECTED FOR RESISTANCE TO MELPHALAN
    MOSCOW, JA
    JOHNSTON, PG
    COLE, D
    POPLACK, DG
    COWAN, KH
    BIOCHEMICAL PHARMACOLOGY, 1995, 49 (08) : 1069 - 1078
  • [49] Plasma pharmacokinetics and tissue distribution of the breast cancer resistance protein (BCRP/ABCG2) inhibitor fumitremorgin C in SCID mice bearing T8 tumors
    T. S. Garimella
    D. D. Ross
    J. L. Eiseman
    J. T. Mondick
    E. Joseph
    T. Nakanishi
    S. E. Bates
    K. S. Bauer
    Cancer Chemotherapy and Pharmacology, 2005, 55 : 101 - 109
  • [50] Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival
    Suvannasankha, A
    Minderman, H
    O'Loughlin, KL
    Nakanishi, T
    Ford, LA
    Greco, WR
    Wetzler, M
    Ross, DD
    Baer, MR
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 127 (04) : 392 - 398